Novabridge Biosciences (NASDAQ:NBP – Get Free Report) insider Mark Arnold Hagler bought 46,000 shares of Novabridge Biosciences stock in a transaction that occurred on Tuesday, November 17th. The shares were acquired at an average price of $0.34 per share, with a total value of $15,640.00. Following the completion of the acquisition, the insider directly owned 276,000 shares of the company’s stock, valued at $93,840. This represents a 20.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Mark Arnold Hagler also recently made the following trade(s):
- On Wednesday, November 18th, Mark Arnold Hagler purchased 184,000 shares of Novabridge Biosciences stock. The stock was acquired at an average price of $0.38 per share, for a total transaction of $69,920.00.
Novabridge Biosciences Stock Down 5.7%
NASDAQ NBP opened at $0.83 on Friday. Novabridge Biosciences has a 1 year low of $0.75 and a 1 year high of $5.19. The business’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.97.
Novabridge Biosciences (NASDAQ:NBP – Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) EPS for the quarter. On average, equities analysts anticipate that Novabridge Biosciences will post -0.54 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on NBP shares. Wall Street Zen upgraded Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Novabridge Biosciences in a report on Thursday, August 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novabridge Biosciences in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.00.
Get Our Latest Research Report on NBP
Novabridge Biosciences Company Profile
Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.
Featured Articles
- Five stocks we like better than Novabridge Biosciences
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Novabridge Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabridge Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
